BioSpace News Archive

Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.

The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.

Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.

AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.

Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma.

The new building will suit multiple life sciences industry segments, including biopharma, medtech, agroscience and more.

Albany NY, United States: A newly compiled business intelligence study at the headquarters of Transparency Market Research has detected stiff competition in the global pulmonary drug delivery systems market.

Curium announced that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market.

Daiichi Sankyo and AstraZeneca have received notification of acceptance of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the U.S. with unresectable or metastatic non-small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Biophytis SA announces it will present and discuss the results of Sarconeos development program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research to be held virtually and on site in Boston from April 20 to April 22, 2022.